The Copenhagen-based company’s drug candidate, RTP-026, is designed to protect the heart from further damage after a severe heart attack. It works by mimicking the body’s own mechanisms for ending inflammation and repairing damaged tissue, without suppressing the immune system more broadly. The technology builds on many years of research at Queen Mary University of London. In a recently completed Phase IIa study, sixty-six patients at high risk of heart damage took part. The results showed promising signs that RTP-026 can protect the heart.

Hunter Capital RTO 1 is already listed on Spotlight. In the reverse takeover, it will acquire ResoTher Pharma by issuing new shares and is then expected to change its name to ResoTher Pharma. ResoTher Pharma’s current shareholders are expected to own about 82% of the combined company.

ResoTher Pharma has raised around SEK 48 million in 2026. If the transaction goes through, the company will also gain access to a SEK 32 million loan facility from Hunter Capital, bringing total financing to around SEK 80 million. The money will fund an international Phase IIb study with more than 200 patients. The company plans to apply for approval of the study at the end of 2026, start it in early 2027, and report results in the third quarter of 2028.

“We have seen promising signs of efficacy in Phase IIa and now have the financing to take the next big step. If we can confirm the effect in a larger patient group, we will have a drug candidate that could become very interesting to the international pharmaceutical industry,” says Anders Kronborg, CEO, ResoTher Pharma, and former CFO and acting CEO of LEO Pharma.